IRVINE, Calif. / Oct 24, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency 1 sales grew 10% Q3 TAVR sales grew 6%; constant currency 1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted 1 EPS... Read More